Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Revive Therapeutics Ltd (OP:RVVTF)

0.0193 -0.0003 (-1.53%)
Delayed Quote Updated: 9:31 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
News headline image
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... 
Via Benzinga
News headline image
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update ↗
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to... 
Via Benzinga
News headline image
Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment ↗
Life sciences company Revive Therapeutics Ltd. 
Via Benzinga
News headline image
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
News headline image
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve 
Via Benzinga
News headline image
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. 
Via Benzinga
News headline image
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More ↗
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January. 
Via Benzinga
News headline image
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders ↗
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.< 
Via Benzinga
News headline image
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials ↗
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). 
Via Benzinga
News headline image
Revive Therapeutics To Raise Up To $5M Via Private Placement ↗
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;. 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022 ↗
 
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 23, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022 ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022 ↗
 
Via Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022 ↗
 
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 
Via Benzinga
News headline image
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 8, 2022 ↗
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
News headline image
Compass Pathways, Allied Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From November 3, 2022 ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
News headline image
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.